AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1180578 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end jejunoileal bypass (30 cm jejunum to 20 cm ileum)
Number of subjects: 150
Study 1180578 — intervention group
Group type: COMPARATOR
Intervention: Other groups under study (not specified)
Number of subjects: 150
Study 31520741 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of etoposide with antiretroviral therapy (ART)
Number of subjects: 0
Study 31520741 — intervention group
Group type: COMPARATOR
Intervention: ART with delayed etoposide upon disease progression
Number of subjects: 0
Study 28973066 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Initiation and Participation Program (TIP)
Number of subjects: 231
Study 28973066 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 231
Study 28039291 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human thrombomodulin (rhTM)
Number of subjects: 92
Study 28039291 — intervention group
Group type: COMPARATOR
Intervention: Control (no anticoagulants)
Number of subjects: 92
Study 25239474 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel antidepressant
Number of subjects: 0
Study 25239474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23061633 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarinol™ G-80 (CLA) 2.5 ml p/d for 8 weeks
Number of subjects: 10
Study 23061633 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic safflower oil (HOSF) 2.5 ml p/d for 8 weeks
Number of subjects: 10
Study 23061633 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10
Study 19401880 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 29
Study 19401880 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 29
Study 17389337 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin, taken orally once daily until disease progression or unacceptable toxicity occurred.
Number of subjects: 55
Study 14977671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy device
Number of subjects: 12
Study 14977671 — intervention group
Group type: COMPARATOR
Intervention: Ice
Number of subjects: 12
Study 14588394 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 0
Study 14588394 — intervention group
Group type: COMPARATOR
Intervention: Medical care
Number of subjects: 0
Study 9291856 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin 3 mg b.i.d.
Number of subjects: 65
Study 9291856 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 65
Study 8438768 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplement (10 mg Zn/d as amino acid chelate) for 90.1 ± 9.2 days
Number of subjects: 162
Study 8438768 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 162
Study 2874221 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 18
Study 2874221 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (Control)
Number of subjects: 18
Study 29431125 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Trainer (VT) intervention group
Number of subjects: 200
Study 29431125 — intervention group
Group type: COMPARATOR
Intervention: Control group (written advice of standard PA recommendation)
Number of subjects: 200
Study 27836073 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt intake
Number of subjects: 35
Study 27836073 — intervention group
Group type: COMPARATOR
Intervention: Low-salt diet
Number of subjects: 35
Study 27836073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary salt intake
Number of subjects: 35
Study 25028655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepsinogen II after H. pylori eradication
Number of subjects: 369
Study 25028655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepsinogen I after H. pylori eradication
Number of subjects: 369
Study 25028655 — intervention group
Group type: EXPERIMENTAL
Intervention: High mononuclear infiltration in corpus
Number of subjects: 369
Study 22690199 — intervention group
Group type: EXPERIMENTAL
Intervention: increased growth monitoring with feedback
Number of subjects: 80
Study 22690199 — intervention group
Group type: EXPERIMENTAL
Intervention: decrease SFs and sugar sweetened beverages
Number of subjects: 80
Study 22690199 — intervention group
Group type: EXPERIMENTAL
Intervention: increase FVs and low‐fat dairy
Number of subjects: 80
Study 20830870 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb preconditioning before induction of ischemia for surgery
Number of subjects: 34
Study 20830870 — intervention group
Group type: COMPARATOR
Intervention: Control group (no limb preconditioning)
Number of subjects: 34
Study 20830870 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb preconditioning
Number of subjects: 34
Study 18761242 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia (group 1, n = 20)
Number of subjects: 40
Study 18761242 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (group 2, n = 20)
Number of subjects: 40
Study 18761242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 16368820 — intervention group
Group type: COMPARATOR
Intervention: 100 mg tramadol IV injection
Number of subjects: 20
Study 12821954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction (median: -77 mmol/24 h)
Number of subjects: 67
Study 12821954 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (median: 44 mmol/24 h)
Number of subjects: 67
Study 12821954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction in hypertensives
Number of subjects: 67
Study 12821954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction in normotensives
Number of subjects: 67
Study 12821954 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation in hypertensives
Number of subjects: 67
Study 12821954 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation in normotensives
Number of subjects: 67
Study 10824450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg t.i.d.
Number of subjects: 44
Study 10824450 — intervention group
Group type: COMPARATOR
Intervention: Placebo 5 mg t.i.d.
Number of subjects: 44
Study 8739071 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 0
Study 8739071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8003236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B P-35
Number of subjects: 0
Study 8003236 — intervention group
Group type: COMPARATOR
Intervention: Crest Complete
Number of subjects: 0
Study 8003236 — intervention group
Group type: COMPARATOR
Intervention: Colgate Precision
Number of subjects: 0
Study 3548294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic heparin treatment (group I)
Number of subjects: 30
Study 3548294 — intervention group
Group type: COMPARATOR
Intervention: Control nonanticoagulated group (group II)
Number of subjects: 30
Study 31991620 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional application
Number of subjects: 30
Study 31991620 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-designed application
Number of subjects: 30
Study 31991620 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 30
Study 28729040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for 2 years
Number of subjects: 300
Study 26069272 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily weight monitoring
Number of subjects: 49
Study 26069272 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 49
Study 24372937 — intervention group
Group type: COMPARATOR
Intervention: Computer Brief Intervention (CBI)
Number of subjects: 714
Study 24372937 — intervention group
Group type: COMPARATOR
Intervention: Therapist Brief Intervention (TBI)
Number of subjects: 714
Study 23057624 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 units of onabotulinumtoxinA
Number of subjects: 224
Study 23057624 — intervention group
Group type: COMPARATOR
Intervention: 30 units of incobotulinumtoxinA
Number of subjects: 224
Study 17904865 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training program based on electromyographic fatigue threshold (EMG(FT))
Number of subjects: 20
Study 17904865 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study 17907851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program (CB)
Number of subjects: 380
Study 17907851 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy-adolescent skills training program (IPT-AST)
Number of subjects: 380
Study 17907851 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 380
Study 15145035 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy with sodium hyaluronate infusion
Number of subjects: 26
Study 15145035 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis
Number of subjects: 26
Study 11896507 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hypertensive group
Number of subjects: 502
Study 11896507 — intervention group
Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 502
Study 11896507 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime BP
Number of subjects: 502
Study 11896507 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time BP
Number of subjects: 502
Study 11896507 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian variability
Number of subjects: 502
Study 11896507 — intervention group
Group type: EXPERIMENTAL
Intervention: Office BP
Number of subjects: 502
Study 11896507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-specific BP values
Number of subjects: 502
Study 9564748 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviant tones in the attended ear
Number of subjects: 0
Study 9564748 — intervention group
Group type: COMPARATOR
Intervention: Unattended-ear deviants
Number of subjects: 0
Study 8180671 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.02-0.05 IU/kg body wt sc daily)
Number of subjects: 36
Study 8180671 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 36
Study 8180671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8180671 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone and Placebo
Number of subjects: 36
Study 3286830 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 626
Study 3286830 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus immunotherapy
Number of subjects: 626
Study 3286830 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 626
Study 3286830 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 626
Study 3286830 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 626
Study 3286830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 626
Study 3286830 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute toxicity
Number of subjects: 626
Study 3286830 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed toxicity
Number of subjects: 626
Study 29683855 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 725
Study 29683855 — intervention group
Group type: COMPARATOR
Intervention: Control (darunavir/cobicistat plus emtricitabine/tenofovir disoproxyl fumarate)
Number of subjects: 725
Study 29683855 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 725
Study 26743886 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystomy (ELC; LC performed within 7 days after a pancreatitis attack)
Number of subjects: 102
Study 26743886 — intervention group
Group type: COMPARATOR
Intervention: Late laparoscopic cholecystomy (LLC; LC performed ≥ 7 days following an attack)
Number of subjects: 102
Study 25539782 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Based Wii Fit exercise (VRWii group)
Number of subjects: 36
Study 25539782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured exercise program)
Number of subjects: 36
Study 25539782 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional exercise (TE group)
Number of subjects: 36
Study 23820947 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant speech
Number of subjects: 0
Study 20637394 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway scope (AWS)
Number of subjects: 25
Study 20637394 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (ML)
Number of subjects: 25
Study 18252784 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation (500 mug/d)
Number of subjects: 452
Study 18252784 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phylloquinone)
Number of subjects: 452
Study 18252784 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (phylloquinone and control)
Number of subjects: 452
Study 16368298 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg/d
Number of subjects: 75
Study 16368298 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg/d
Number of subjects: 75
Study 16368298 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 320 mg/d
Number of subjects: 75
Study 16368298 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan (all doses)
Number of subjects: 75
Study 16368298 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan in patients with diabetes
Number of subjects: 75
Study 12525717 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta (IFNβ)
Number of subjects: 33
Study 12525717 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 33
Study 10960199 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed (42 degrees C) humidified O(2)
Number of subjects: 30
Study 10960199 — intervention group
Group type: COMPARATOR
Intervention: Routine O(2) therapy (control group)
Number of subjects: 30
Study 8773861 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg.kg‐1 and 5 mg.kg‐1 thiopentone (group MT)
Number of subjects: 150
Study 8773861 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1 (group P)
Number of subjects: 150
Study 8773861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg.kg‐1 and 5 mg.kg‐1 thiopentone (group LT)
Number of subjects: 150
Study 8773861 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine-thiopentone group (group LT)
Number of subjects: 150
Study 1522692 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 10
Study 1522692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6499510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium (average dose 165.4 mg/day)
Number of subjects: 18
Study 6499510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 18
Study 6499510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30620944 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible respiratory function monitor (RFM)
Number of subjects: 106
Study 30620944 — intervention group
Group type: COMPARATOR
Intervention: Masked respiratory function monitor (RFM)
Number of subjects: 106
Study 29760878 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator II™-instrument-assisted cervical and thoracic spine manipulation plus light massage, mobilisation, range of motion exercises, and home advice about heat application
Number of subjects: 24
Study 29760878 — intervention group
Group type: COMPARATOR
Intervention: Sham-Activator II™-instrument-assisted manipulation (set to zero impulse) plus gentle touch of cervical and thoracic spinal regions
Number of subjects: 24
Study 26667358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Survivorship Intervention-Sexual Health (CSI-SH)
Number of subjects: 70
Study 26667358 — intervention group
Group type: COMPARATOR
Intervention: Assessment Only (AO)
Number of subjects: 70
Study 24252035 — intervention group
Group type: EXPERIMENTAL
Intervention: BUC + MTX
Number of subjects: 55
Study 24252035 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 55
Study 22256805 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg once daily) and Asunaprevir (600 mg twice daily) alone (group A)
Number of subjects: 21
Study 22256805 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg once daily) and Asunaprevir (600 mg twice daily) in combination with peginterferon alfa‐2a and ribavirin (group B)
Number of subjects: 21
Study 20410884 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-790052, a small molecule inhibitor of the HCV NS5A protein, administered as a single 100-mg dose.
Number of subjects: 2
Study 20410884 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-790052
Number of subjects: 2
Study 17380550 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthwash (mixture of tea tree, peppermint, and lemon)
Number of subjects: 32
Study 17380550 — intervention group
Group type: COMPARATOR
Intervention: Tantum (benzydamine hydrochloride)
Number of subjects: 32
Study 16356894 — intervention group
Group type: EXPERIMENTAL
Intervention: Abuse assessment and receipt of a wallet-size referral card
Number of subjects: 233
Study 16356894 — intervention group
Group type: EXPERIMENTAL
Intervention: Abuse assessment, receipt of a wallet-size referral card, and nurse case management sessions
Number of subjects: 233
Study 16356894 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (clinically-referred sample of children)
Number of subjects: 233
Study 16356894 — intervention group
Group type: EXPERIMENTAL
Intervention: Children ages 18 months to 5 years
Number of subjects: 233
Study 16356894 — intervention group
Group type: EXPERIMENTAL
Intervention: Teenagers
Number of subjects: 233
Study 12048339 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient appointment guidebook
Number of subjects: 277
Study 12048339 — intervention group
Group type: COMPARATOR
Intervention: Standard appointment reminder letter
Number of subjects: 277
Study 10378967 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy
Number of subjects: 0
Study 7775792 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (Group 1)
Number of subjects: 51
Study 7775792 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline lavage followed by activated charcoal (Group 2)
Number of subjects: 51
Study 7775792 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal followed by saline lavage followed by activated charcoal (Group 3)
Number of subjects: 51
Study 2277576 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml isobaric tetracaine
Number of subjects: 100
Study 2277576 — intervention group
Group type: COMPARATOR
Intervention: 1 ml isobaric tetracaine
Number of subjects: 100
Study 6451138 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-traction treatment for up to three 1-hour sessions in 1 week
Number of subjects: 82
Study 6451138 — intervention group
Group type: COMPARATOR
Intervention: Corset and advised to rest (Control)
Number of subjects: 82
Study 31637733 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 0
Study 31637733 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (1000 and 1500 mg)
Number of subjects: 0
Study 29547962 — intervention group
Group type: EXPERIMENTAL
Intervention: One open-label placebo pill per day
Number of subjects: 100
Study 29547962 — intervention group
Group type: EXPERIMENTAL
Intervention: Four open-label placebo pills per day
Number of subjects: 100
Study 29547962 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 100
Study 26465101 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% gel of unripe banana peel
Number of subjects: 60
Study 26465101 — intervention group
Group type: COMPARATOR
Intervention: Control group (gel containing no active ingredient)
Number of subjects: 60
Study 23965205 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L (luteal phase)
Number of subjects: 80
Study 23965205 — intervention group
Group type: COMPARATOR
Intervention: Group F (follicular phase)
Number of subjects: 80
Study 21665107 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible foil training for shoulder pain group 1
Number of subjects: 30
Study 21665107 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible bands training for shoulder pain group 2
Number of subjects: 30
Study 21665107 — intervention group
Group type: COMPARATOR
Intervention: Non-symptomatic subjects
Number of subjects: 30
Study 19332659 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological sex steroid replacement (transdermal estradiol and vaginal progesterone)
Number of subjects: 34
Study 19332659 — intervention group
Group type: COMPARATOR
Intervention: Standard sex steroid replacement (oral ethinylestradiol and norethisterone)
Number of subjects: 34
Study 16387822 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal definition of myocardial infarction
Number of subjects: 0
Study 16387822 — intervention group
Group type: EXPERIMENTAL
Intervention: Stringent definition of myocardial infarction
Number of subjects: 0
Study 16387822 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI major bleeding definition
Number of subjects: 0
Study 15884282 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg vaginal misoprostol, six hourly for a maximum of four doses
Number of subjects: 38
Study 15884282 — intervention group
Group type: COMPARATOR
Intervention: 200 microg oral misoprostol, six hourly for a maximum of four doses
Number of subjects: 38
Study 15884282 — intervention group
Group type: COMPARATOR
Intervention: 200 microg oral misoprostol
Number of subjects: 38
Study 15884282 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg vaginal misoprostol
Number of subjects: 38
Study 10695646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 23
Study 10695646 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 23
Study 10695646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23